Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1795199 Target Snapshot

Receptor-interacting serine/threonine-protein kinase 3 · SINGLE PROTEIN · Homo sapiens

702Compounds
134Assays
22Approved Drugs
655.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9Y572. Use UniProt Q9Y572 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9Y572 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor-interacting serine/threonine-protein kinase 3 as ChEMBL target CHEMBL1795199, mapped to UniProt Q9Y572. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Receptor-interacting serine/threonine-protein kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1795199
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y572
Receptor-interacting serine/threonine-protein kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Receptor-interacting serine/threonine-protein kinase 3 is the right protein anchor across sources, using UniProt Q9Y572 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor-interacting serine/threonine-protein kinase 3
UniProt AccessionQ9Y572
Component TypeProtein
Sequence Length518 aa

Receptor-interacting serine/threonine-protein kinase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Receptor-interacting serine/threonine-protein kinase 3, mapped to UniProt Q9Y572. Sequence length is 518 aa.

Mapped IDQ9Y572
Review nameReceptor-interacting serine/threonine-protein kinase 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

22
Approved
7
Phase III
13
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50306.0
EC502.0
KD347.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4439913 9.52 IC50 0.3 Preclinical
CHEMBL4470115 9.52 IC50 0.3 Preclinical
CHEMBL4779280 8.89 IC50 1.3 Preclinical
CHEMBL5407694 8.87 Kd 1.35 Preclinical
CHEMBL1171837 8.8 IC50 1.6 Approved
CHEMBL2028663 8.7 IC50 2.0 Approved
CHEMBL4455682 8.54 IC50 2.9 Preclinical
CHEMBL400402 8.52 Kd 3.0 Preclinical
CHEMBL4441118 8.19 IC50 6.5 Preclinical
CHEMBL4861646 8.14 Kd 7.2 Preclinical
Distribution

pChEMBL Value Distribution

115
5.0
35
5.5
26
6.0
28
6.5
63
7.0
9
7.5
7
8.0
13
8.5
2
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
ENCORAFENIB
CHEMBL3301612
Approved 2018
LENVATINIB
CHEMBL1289601
Approved 2015
DABRAFENIB
CHEMBL2028663
Approved 2013
IBRUTINIB
CHEMBL1873475
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
Assay Landscape

Assay Landscape

134
Total Assays
277
Tested Compounds
3
Assay Types
Binding — 131 assays, 277 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 59 173 6.0
cell-based format 47 35 6.3
assay format 15 29 7.4
subcellular format 7 40 6.2
tissue-based format 3 0
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine